US74638P1093 - ADR
PURPLE BIOTECH LTD-ADR
NASDAQ:PPBT (12/4/2024, 8:04:59 PM)
After market: 4.89 +0.07 (+1.56%)4.815
-1.75 (-26.71%)
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
PURPLE BIOTECH LTD-ADR
4 Oppenheimer St., Science Park
Rehovot 7670104
P: 97239333121
CEO: Gil Efron
Employees: 20
Website: https://purple-biotech.com/
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Let's have a look at the gap up and gap down stocks in today's session.
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company...
Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024...
Here you can normally see the latest stock twits on PPBT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: